FRSW-117

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameFRSW-117
Drug Alias NamePEG-Recombinant FVIII-Fc fusion protein注射用重组人凝血因子Ⅷ-Fc融合蛋白注射用培重组人凝血因子Ⅷ-Fc融合蛋白FRSW-117
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCoagulation factor X stimulantsBlood coagulation pathway activationCoagulation factor VIII replacements
TargetsCoagulation factor XCoagulation factor VIII
Therapy Area/IndicationsHemophilia ABlood Coagulation Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesKaifeng Pharmaceutical (Group) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Shengsi Biopharmaceutical Co LtdJiangsu Gensciences lncBeijing Furen Ruihui Biomedical Research Institute Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHemophilia ABlood Coagulation Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A